Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04368988




Registration number
NCT04368988
Ethics application status
Date submitted
24/04/2020
Date registered
30/04/2020
Date last updated
10/04/2023

Titles & IDs
Public title
Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant
Scientific title
A 2-Part, Phase 1/2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-M™ Adjuvant In Healthy Subjects
Secondary ID [1] 0 0
2019nCoV-101
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
COVID-19 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - SARS-CoV-2 rS - Phase 1
Treatment: Other - SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1
Other interventions - Normal saline solution (NSS), Placebo - Phase 1
Other interventions - Normal saline solution (NSS), Placebo - Phase 2
Treatment: Other - SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1
Other interventions - Normal saline solution (NSS), Placebo, Day 21 - Phase 1
Treatment: Other - SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2

Placebo comparator: Placebo - Phase 1 - 2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.

Experimental: SARS-CoV-2 rS - 25 µg without Matrix-M - Phase 1 - 2 doses of SARS-CoV-2 rS - 25 µg, 1 dose each on Days 0 and 21.

Experimental: SARS-CoV-2 rS - 5 µg + 50 µg Matrix-M - Phase 1 - 2 doses of SARS-CoV-2 rS - 5 µg + 50 µg Matrix-M (mixed together for each injection), 1 dose each on Days 0 and 21.

Experimental: SARS-CoV-2 rS - 25 µg + 50 µg Matrix-M - Phase 1 - 2 doses of SARS-CoV-2 rS - 25 µg + 50 µg Matrix-M (mixed together for each injection), 1 dose each on Days 0 and 21.

Experimental: SARS-CoV-2 rS - 25 µg + 50 µg Matrix-M then Placebo - Phase 1 - 1 dose of SARS-CoV-2 rS - 25 µg + 50 µg Matrix-M (mixed together for injection), on Day 0 followed by 1 dose of Placebo on Day 21.

Placebo comparator: Placebo - Phase 2 - 3 doses of Placebo (Saline), 1 dose each on Days 0, 21, and 189.

Experimental: SARS-CoV-2 rS - 5/5 µg + 50 µg Matrix-M - Phase 2 - 2 doses of SARS-CoV-2 rS - 5 µg + 50 µg Matrix-M (co-formulated), 1 dose each on Days 0 and 21, followed by 1 dose of Placebo on Day 189.

Experimental: SARS-CoV-2 rS - Alternating 5/5 µg + 50 µg Matrix-M - Phase 2 - 1 dose of SARS-CoV-2 rS - 5 µg + 50 µg Matrix-M (co-formulated) on Day 0 then 1 dose of Placebo on Day 21 followed by 1 dose of SARS-CoV-2 rS - 5 µg + 50 µg Matrix-M (co-formulated) on Day 189.

Experimental: SARS-CoV-2 rS - 25/25 µg + 50 µg Matrix-M - Phase 2 - 2 doses of SARS-CoV-2 rS - 25 µg + 50 µg Matrix-M (co-formulated), 1 dose each on Days 0 and 21, followed by 1 dose of Placebo on Day 189.

Experimental: SARS-CoV-2 rS - 25 µg + 50 µg Matrix-M - Phase 2 - 1 dose of SARS-CoV-2 rS - 25 µg + 50 µg Matrix-M (co-formulated) on Day 0 then 2 doses of Placebo, 1 dose each on Days 21 and 189.

Experimental: SARS-CoV-2 rS - 5/5/5 µg + 50 µg Matrix-M - Phase 2 - 3 doses of SARS-CoV-2 rS - 5 µg + 50 µg Matrix-M (co-formulated), 1 dose each on Day 0, Day 21, and Day 189.

Experimental: SARS-CoV-2 rS - 5 µg + 50 µg Matrix-M - Phase 2 - 1 dose of SARS-CoV-2 rS - 5 µg + 50 µg Matrix-M (co-formulated) on Day 0 then 2 doses of Placebo, 1 dose each on Days 21 and 189.


Treatment: Other: SARS-CoV-2 rS - Phase 1
Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS (0.6 mL) on Days 0 and 21.

Treatment: Other: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1
Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS mixed with Matrix-M adjuvant (0.6 mL) on Days 0 and 21.

Other interventions: Normal saline solution (NSS), Placebo - Phase 1
Alternating intramuscular (deltoid) injections of placebo (0.6 mL) on Days 0 and 21.

Other interventions: Normal saline solution (NSS), Placebo - Phase 2
Intramuscular (deltoid) injections of placebo (0.5 mL).

Treatment: Other: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1
Intramuscular (deltoid) injection of SARS-CoV-2 rS mixed with Matrix-M adjuvant (0.6 mL) on Day 0.

Other interventions: Normal saline solution (NSS), Placebo, Day 21 - Phase 1
Intramuscular injection of placebo (0.6 mL) in alternate deltoid on Day 21.

Treatment: Other: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2
Intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M adjuvant (0.5 mL).
Intervention code [1] 0 0
Treatment: Other
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Participants with Solicited Adverse Events (AEs) - Phase 1
Timepoint [1] 0 0
28 days
Primary outcome [2] 0 0
Safety Laboratory Values (Serum Chemistry, Hematology) - Phase 1
Timepoint [2] 0 0
28 days
Primary outcome [3] 0 0
Serum Immunoglobulin G (IgG) Antibody Levels Expressed as Geometric Mean Titers (GMTs) - Phase 1
Timepoint [3] 0 0
21 days
Primary outcome [4] 0 0
Serum Immunoglobulin G (IgG) Antibody Levels Expressed as Geometric Mean Titers (GMTs) - Phase 1
Timepoint [4] 0 0
35 days
Primary outcome [5] 0 0
Serum IgG Antibody Levels Expressed as Geometric Mean Fold Rises (GMFRs) - Phase 1
Timepoint [5] 0 0
35 days
Primary outcome [6] 0 0
Serum IgG Antibody Levels Expressed as Seroconversion Rates (SCRs) - Phase 1
Timepoint [6] 0 0
35 days
Primary outcome [7] 0 0
Serum IgG Antibody Levels Expressed as GMEUs - Phase 2
Timepoint [7] 0 0
Day 35
Primary outcome [8] 0 0
Serum IgG Antibody Levels Expressed as GMFRs - Phase 2
Timepoint [8] 0 0
Day 35
Primary outcome [9] 0 0
Serum IgG Antibody Levels Expressed as SCRs - Phase 2
Timepoint [9] 0 0
Day 35
Primary outcome [10] 0 0
Participants with Solicited Adverse Events (AEs) - Phase 2
Timepoint [10] 0 0
28 days
Primary outcome [11] 0 0
Participants with Unsolicited AEs - Phase 2
Timepoint [11] 0 0
35 days
Secondary outcome [1] 0 0
Participants with Unsolicited AEs - Phase 1
Timepoint [1] 0 0
49 days
Secondary outcome [2] 0 0
Participants with Abnormal Vital Signs - Phase 1
Timepoint [2] 0 0
21 days
Secondary outcome [3] 0 0
Changes from Baseline in Body Temperature - Phase 1
Timepoint [3] 0 0
189 days
Secondary outcome [4] 0 0
Changes from Baseline in Blood Pressure - Phase 1
Timepoint [4] 0 0
189 days
Secondary outcome [5] 0 0
Changes from Baseline in Pulse Rate - Phase 1
Timepoint [5] 0 0
189 days
Secondary outcome [6] 0 0
Participants with MAAEs - Phase 1
Timepoint [6] 0 0
105 days
Secondary outcome [7] 0 0
Participants with Related MAAEs; Serious Adverse Events (SAEs); and Adverse Events of Special Interest (AESI) - Phase 1
Timepoint [7] 0 0
386 days
Secondary outcome [8] 0 0
Assessment of Serum IgG Antibody Levels Expressed as GMTs at Multiple Time Points - Phase 1
Timepoint [8] 0 0
189 days
Secondary outcome [9] 0 0
Assessment of Serum IgG Antibody Levels Expressed as GMFRs at Multiple Time Points - Phase 1
Timepoint [9] 0 0
189 days
Secondary outcome [10] 0 0
Assessment of Serum IgG Antibody Levels Expressed as SCRs at Multiple Time Points - Phase 1
Timepoint [10] 0 0
189 days
Secondary outcome [11] 0 0
Assessment of Serum IgG Antibody Levels Expressed by Seroresponse Rates (SRRs) at Multiple Time Points - Phase 1
Timepoint [11] 0 0
189 days
Secondary outcome [12] 0 0
Angiotensin-Converting Enzyme 2 (ACE2) Receptor Binding Inhibition Assay Expressed as GMTs - Phase 1
Timepoint [12] 0 0
189 days
Secondary outcome [13] 0 0
ACE2 Receptor Binding Inhibition Assay Expressed as GMFRs - Phase 1
Timepoint [13] 0 0
189 days
Secondary outcome [14] 0 0
ACE2 Receptor Binding Inhibition Assay Expressed as SCRs - Phase 1
Timepoint [14] 0 0
189 days
Secondary outcome [15] 0 0
ACE2 Receptor Binding Inhibition Assay Expressed as SRRs - Phase 1
Timepoint [15] 0 0
189 days
Secondary outcome [16] 0 0
Neutralizing Antibody Activity Expressed as GMTs - Phase 1
Timepoint [16] 0 0
49 days
Secondary outcome [17] 0 0
Neutralizing Antibody Activity Expressed as GMFRs - Phase 1
Timepoint [17] 0 0
49 days
Secondary outcome [18] 0 0
Neutralizing Antibody Activity Expressed as SCRs - Phase 1
Timepoint [18] 0 0
49 days
Secondary outcome [19] 0 0
Neutralizing Antibody Activity Expressed as SRRs - Phase 1
Timepoint [19] 0 0
49 days
Secondary outcome [20] 0 0
Assessment of Cell-Mediated (T helper 1 [Th1]/T helper 2 [Th2]) Pathways - Phase 1
Timepoint [20] 0 0
28 days
Secondary outcome [21] 0 0
Assessment of Serum IgG Antibody Levels Expressed as GMTs - Phase 2
Timepoint [21] 0 0
35 days
Secondary outcome [22] 0 0
Assessment of Serum IgG Antibody Levels Expressed as GMFRs - Phase 2
Timepoint [22] 0 0
35 days
Secondary outcome [23] 0 0
Assessment of Serum IgG Antibody Levels Expressed as SCRs (= 4-fold change) - Phase 2
Timepoint [23] 0 0
35 days
Secondary outcome [24] 0 0
Assessment of Serum IgG Antibody Levels Expressed as GMEUs at Multiple Time Points - Phase 2
Timepoint [24] 0 0
357 days
Secondary outcome [25] 0 0
Assessment of Serum IgG Antibody Levels Expressed as GMFRs at Multiple Time Points - Phase 2
Timepoint [25] 0 0
357 days
Secondary outcome [26] 0 0
Assessment of Serum IgG Antibody Levels Expressed as SCRs (= 4-fold change) at Multiple Time Points - Phase 2
Timepoint [26] 0 0
357 days
Secondary outcome [27] 0 0
ACE2 Receptor Binding Inhibition Assay Expressed as GMTs - Phase 2
Timepoint [27] 0 0
357 days
Secondary outcome [28] 0 0
ACE2 Receptor Binding Inhibition Assay Expressed as GMFRs - Phase 2
Timepoint [28] 0 0
357 days
Secondary outcome [29] 0 0
ACE2 Receptor Binding Inhibition Assay Expressed as SCRs - Phase 2
Timepoint [29] 0 0
357 days
Secondary outcome [30] 0 0
Neutralizing Antibody Activity Expressed as GMTs - Phase 2
Timepoint [30] 0 0
357 days
Secondary outcome [31] 0 0
Neutralizing Antibody Activity Expressed as GMFRs - Phase 2
Timepoint [31] 0 0
357 days
Secondary outcome [32] 0 0
Neutralizing Antibody Activity Expressed as SCRs (= 4-fold change) - Phase 2
Timepoint [32] 0 0
357 days
Secondary outcome [33] 0 0
Assessment of Serum IgG Antibody Levels Expressed as GMTs - Phase 2 Boost
Timepoint [33] 0 0
546 days
Secondary outcome [34] 0 0
Assessment of Serum IgG Antibody Levels Expressed as GMFRs - Phase 2 Boost
Timepoint [34] 0 0
546 days
Secondary outcome [35] 0 0
Participants with MAAEs - Phase 2
Timepoint [35] 0 0
217 days
Secondary outcome [36] 0 0
Participants with Related MAAEs; SAEs; and AESIs - Phase 2
Timepoint [36] 0 0
357 days
Secondary outcome [37] 0 0
Participants with Abnormal Vital Signs - Phase 2
Timepoint [37] 0 0
21 days
Secondary outcome [38] 0 0
Changes from Baseline in Body Temperature - Phase 2
Timepoint [38] 0 0
189 days
Secondary outcome [39] 0 0
Changes from Baseline in Blood Pressure - Phase 2
Timepoint [39] 0 0
189 days
Secondary outcome [40] 0 0
Changes from Baseline in Pulse Rate - Phase 2
Timepoint [40] 0 0
189 days
Secondary outcome [41] 0 0
Participants with SARS-CoV-2 Positivity - Phase 2
Timepoint [41] 0 0
161 days
Secondary outcome [42] 0 0
Assessment of SARS-CoV-2 by Qualitative PCR - Phase 2
Timepoint [42] 0 0
161 days
Secondary outcome [43] 0 0
Assessment of Cell-Mediated (Th1/Th2) Pathways - Phase 2
Timepoint [43] 0 0
28 days

Eligibility
Key inclusion criteria
Inclusion Criteria (Part 1):

* Healthy adult males or females between 18 and 59 years of age, inclusive, at screening. Healthy status will be determined by the investigator based on medical history, clinical laboratory results, vital sign measurements, and physical examination at screening.
* The participant has a body mass index 17 to 35 kg/m2, inclusive, at screening.
* Willing and able to give informed consent prior to study enrollment and comply with study procedures.
* Female participants of childbearing potential (defined as any female who has experienced menarche and who is NOT surgically sterile [ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy] or postmenopausal [defined as amenorrhea at least 12 consecutive months or documented plasma follicle-stimulating hormone (FSH) level =40 mIU/mL]) must agree to be heterosexually inactive from at least 21 days prior to enrollment and through 6 months after the last vaccination OR agree to consistently use any of the described methods of contraception from at least 21 days prior to enrollment and through 6 months after the last vaccination.
Minimum age
18 Years
Maximum age
84 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Exclusion Criteria (Part 1):

* Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care, inclusive of changes in medication in the past 2 months indicating that chronic illness/disease is not stable (at the discretion of the investigator). This includes any current workup of undiagnosed illness that could lead to a new condition.
* Chronic disease inclusive of: a) hypertension uncontrolled for age according to the Eighth Joint National Committee (JNC 8) guidelines; b) congestive heart failure by New York Heart Association (NYHA) functional classification of greater or equal to II; c) chronic obstructive pulmonary disease by Global Initiative for Obstructive Lung Disease (GOLD) classification of greater or equal to 2; d) recent (within 6 months prior to first study vaccination) exacerbation of coronary artery disease as manifested by cardiac intervention, addition of new cardiac medications for control of symptoms, or unstable angina; e) asthma (diagnosed by spirometry showing reversibility of disease and must meet at least the Step 1 classification with current prescription/use of medications to control symptoms); f) diabetes requiring use of medicine (insulin or oral) or not controlled with diet.
* Participation in research involving an investigational product (drug/biologic/device) within 45 days prior to first study vaccination.
* History of a confirmed diagnosis of SARS or COVID-19 disease (confirmed by a specific test for each disease) or known exposure to a SARS-CoV-2 positive confirmed close contact (eg, family member, housemate, daycare provider, aged parent requiring care), at the discretion of the investigator.
* Currently working in an occupation with a high risk of exposure to SARS-CoV-2 (eg, healthcare worker, emergency response personnel).
* Currently taking any product (investigational or off-label) for prevention of COVID-19 disease.
* Positive rapid test for SARS-CoV-2 (either ELISA IgG or PCR) at screening or prior to first vaccination. Testing may be repeated during the screening period if exposure to SARS-CoV-2 is suspected, at the discretion of the investigator.
* Received influenza vaccination within 14 days prior to first study vaccination, or any other vaccine within 4 weeks prior to first study vaccination.
* Any autoimmune or immunodeficiency disease/condition (iatrogenic or congenital).
* Chronic administration (defined as more than 14 continuous days) of immunosuppressant, systemic glucocorticosteroids, or other immune-modifying drugs within 90 days prior to first study vaccination; or anticipation of the need for immunosuppressive treatment within 6 months after last vaccination.
* Received immunoglobulin, blood-derived products, or other immunosuppressant drugs within 90 days prior to first study vaccination.
* Any acute illness concurrent or within 14 days prior to first study vaccination (medical history and/or physical examination) or documented temperature of >38°C during this period. This includes respiratory or constitutional symptoms consistent with SARS-CoV-2 (COVID-19) exposure (ie, cough, sore throat, difficulty breathing).
* Known disturbance of coagulation (iatrogenic or congenital).
* Evidence of Hepatitis B or C or HIV by laboratory testing.
* A positive test result for drugs of abuse (except a positive test result associated with prescription medication that has been reviewed and approved by the investigator) or alcohol at screening.
* Any neurological disease or history of significant neurological disorder (eg, meningitis, seizures, multiple sclerosis, vasculitis, migraines, Guillain-Barré syndrome [genetic/congenital or acquired]).
* Active cancer (malignancy) within 5 years prior to first study vaccination (with the exception of adequately treated non-melanomatous skin carcinoma, at the discretion of the investigator)
* Vital sign (blood pressure, pulse, temperature) abnormalities of toxicity grade >1.
* Clinical laboratory abnormalities of toxicity grade >1 for selected serum chemistry and hematology parameters
* Any known allergies to products contained in the investigational product or latex allergy.
* Women who are pregnant, breastfeeding or who plan to become pregnant during the study.
* History of alcohol abuse or drug addiction within 1 year prior to the first study vaccination.
* Any condition that, in the opinion of the investigator, would pose a health risk to the participant if enrolled or could interfere with evaluation of the study vaccine or interpretation of study results (including neurologic or psychiatric conditions deemed likely to impair the quality of safety reporting).
* Study team member or first-degree relative of any study team member (inclusive of sponsor, PPD, and site personnel involved in the study).

Inclusion Criteria (Part 2):

* Healthy adult males or females between 18 and 84 years of age, inclusive, at screening who are of legal adult age in their local jurisdiction. Healthy status will be determined by the investigator based on medical history, clinical laboratory results, vital sign measurements, and physical examination at screening.
* The participant has a body mass index 17 to 35 kg/m2, inclusive, at screening.
* Willing and able to give informed consent prior to study enrollment and comply with study procedures.
* Female participants of childbearing potential (defined as any female who has experienced menarche and who is NOT surgically sterile [ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy] or postmenopausal [defined as amenorrhea at least 12 consecutive months or documented plasma FSH level =40 mIU/mL]) must agree to be heterosexually inactive from at least 21 days prior to enrollment and through 6 months after the last vaccination OR agree to consistently use any of the following methods of contraception from at least 21 days prior to enrollment and through 6 months after the last vaccination.

Exclusion Criteria (Part 2):

* Participants who are having any current workup of undiagnosed illness within the last 8 weeks, which is either participant-reported or has been clinician-assessed, that could lead to a new condition diagnosis.
* Participation in research involving an investigational product (drug/biologic/device) within 45 days prior to first study vaccination.
* History of a confirmed diagnosis of SARS or history of a confirmed diagnosis of COVID-19 disease resulting in medical intervention.
* Received influenza vaccination within 14 days prior to first study vaccination, or any other vaccine within 4 weeks prior to first study vaccination.
* Have clinically significant chronic cardiovascular, endocrine, gastrointestinal/ hepatic, renal, neurological, respiratory, or other medical disorders not excluded by other exclusion criteria, that are assessed by the Investigator as being clinically unstable within the prior 4 weeks evidenced by: a) hospitalization for the condition, including day surgical interventions, b) new significant organ function deterioration, c) needing addition of new treatments or major dose adjustments of current treatments.
* Diabetes mellitus requiring insulin therapy (either type 1 or type 2 diabetes mellitus).
* Chronic obstructive pulmonary disease with a history of an acute exacerbation of any severity in the prior year.
* Any history of congestive heart failure.
* Any history of chronic kidney disease (the presence of impaired or reduced kidney function lasting at least 3 months). Clinical validation of potential cases of chronic kidney disease should be conducted.
* Evidence of unstable coronary artery disease as manifested by cardiac intervention, addition of new cardiac medications for control of symptoms, or unstable angina in the past 3 months.
* History of chronic neurological disorders that have required prior specialist physician review for diagnosis and management (such as multiple sclerosis, dementia, transient ischemic attacks, Parkinson's disease, degenerative neurological conditions, neuropathy, and epilepsy) or a history of stroke or previous neurological disorder within 12 months with residual symptoms. Participants with a history of migraine or chronic headaches or nerve root compression that have been stable on treatment for the last 4 weeks are not excluded.
* Any autoimmune or immunodeficiency disease/condition (iatrogenic or congenital).
* Chronic administration (defined as more than 14 continuous days) of immunosuppressants, systemic glucocorticosteroids reaching an immunosuppressive dose, or other immune-modifying drugs within 90 days prior to first study vaccination.
* Received immunoglobulin, blood-derived products, or other immunosuppressant drugs within 90 days prior to first study vaccination.
* Known disturbance of coagulation (iatrogenic or congenital).
* Active cancer (malignancy) within 5 years prior to first study vaccination (with the exception of adequately treated non-melanomatous skin carcinoma, at the discretion of the investigator).
* Any known allergies to products contained in the investigational product or latex allergy.
* Women who are breastfeeding or who plan to become pregnant during the study.
* History of alcohol abuse or drug addiction within one year prior to the first study vaccination.
* Any condition that, in the opinion of the investigator, would pose a health risk to the subject if enrolled or could interfere with evaluation of the study vaccine or interpretation of study results (including neurologic or psychiatric conditions deemed likely to impair the quality of safety reporting).
* Study team member or first-degree relative of any study team member (inclusive of sponsor, PPD, and site personnel involved in the study).

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
25/05/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/06/2022
Sample size
Target
Accrual to date
Final
1419
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,VIC
Recruitment hospital [1] 0 0
Paratus Clinical Research - Canberra - Phase 2 - Bruce
Recruitment hospital [2] 0 0
Paratus Clinical Research - Western Sydney - Phase 2 - Blacktown
Recruitment hospital [3] 0 0
Paratus Clinical Research - Central Coast - Phase 2 - Kanwal
Recruitment hospital [4] 0 0
Australian Clinical Research Network - Phase 2 - Maroubra
Recruitment hospital [5] 0 0
Scientia Clinical Research Limited - Phase 2 - Randwick
Recruitment hospital [6] 0 0
Q Pharm Pty Limited - Phase 1 - Herston
Recruitment hospital [7] 0 0
University of the Sunshine Coast, Health Hub Morayfield - Phase 2 - Morayfield
Recruitment hospital [8] 0 0
University of the Sunshine Coast - Phase 2 - Sippy Downs
Recruitment hospital [9] 0 0
Barwon Health - Phase 2 - Geelong
Recruitment hospital [10] 0 0
Center for Clinical Studies - Phase 1 and Phase 2 - Melbourne
Recruitment postcode(s) [1] 0 0
2617 - Bruce
Recruitment postcode(s) [2] 0 0
2148 - Blacktown
Recruitment postcode(s) [3] 0 0
2259 - Kanwal
Recruitment postcode(s) [4] 0 0
2035 - Maroubra
Recruitment postcode(s) [5] 0 0
2031 - Randwick
Recruitment postcode(s) [6] 0 0
4006 - Herston
Recruitment postcode(s) [7] 0 0
4506 - Morayfield
Recruitment postcode(s) [8] 0 0
4556 - Sippy Downs
Recruitment postcode(s) [9] 0 0
3220 - Geelong
Recruitment postcode(s) [10] 0 0
3181 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Georgia
Country [2] 0 0
United States of America
State/province [2] 0 0
Idaho
Country [3] 0 0
United States of America
State/province [3] 0 0
Kansas
Country [4] 0 0
United States of America
State/province [4] 0 0
Kentucky
Country [5] 0 0
United States of America
State/province [5] 0 0
Maryland
Country [6] 0 0
United States of America
State/province [6] 0 0
Ohio

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novavax
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Coalition for Epidemic Preparedness Innovations
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
2019nCoV-101 is a 2-part, randomized, observer-blinded, placebo-controlled, Phase 1/2 trial. Part 1 (Phase 1) of the study is designed to evaluate the safety and immunogenicity of SARS-CoV-2 rS nanoparticle vaccine with or without Matrix-M adjuvant in 131 healthy participants = 18 to 59 (inclusive) years of age at 2 sites in Australia. An interim analysis of Part 1 safety and immunogenicity will be performed prior to optional expansion to Part 2. Part 2 (Phase 2) of the study is designed to evaluate the immunogenicity, safety, and preliminary efficacy of a single construct of SARS-CoV-2 rS nanoparticle vaccine with Matrix-M adjuvant in up to 1,500 healthy participants = 18 to 84 (inclusive) years of age at up to 40 sites across Australia and/or the United States.
Trial website
https://clinicaltrials.gov/study/NCT04368988
Trial related presentations / publications
Mallory RM, Formica N, Pfeiffer S, Wilkinson B, Marcheschi A, Albert G, McFall H, Robinson M, Plested JS, Zhu M, Cloney-Clark S, Zhou B, Chau G, Robertson A, Maciejewski S, Hammond HL, Baracco L, Logue J, Frieman MB, Smith G, Patel N, Glenn GM; Novavax 2019nCoV101 Study Group. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2022 Nov;22(11):1565-1576. doi: 10.1016/S1473-3099(22)00420-0. Epub 2022 Aug 10.
Formica N, Mallory R, Albert G, Robinson M, Plested JS, Cho I, Robertson A, Dubovsky F, Glenn GM; 2019nCoV-101 Study Group. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial. PLoS Med. 2021 Oct 1;18(10):e1003769. doi: 10.1371/journal.pmed.1003769. eCollection 2021 Oct.
Tian JH, Patel N, Haupt R, Zhou H, Weston S, Hammond H, Logue J, Portnoff AD, Norton J, Guebre-Xabier M, Zhou B, Jacobson K, Maciejewski S, Khatoon R, Wisniewska M, Moffitt W, Kluepfel-Stahl S, Ekechukwu B, Papin J, Boddapati S, Jason Wong C, Piedra PA, Frieman MB, Massare MJ, Fries L, Bengtsson KL, Stertman L, Ellingsworth L, Glenn G, Smith G. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat Commun. 2021 Jan 14;12(1):372. doi: 10.1038/s41467-020-20653-8.
Guebre-Xabier M, Patel N, Tian JH, Zhou B, Maciejewski S, Lam K, Portnoff AD, Massare MJ, Frieman MB, Piedra PA, Ellingsworth L, Glenn G, Smith G. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine. 2020 Nov 25;38(50):7892-7896. doi: 10.1016/j.vaccine.2020.10.064. Epub 2020 Oct 23.
Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H, Smith G, Patel N, Frieman MB, Haupt RE, Logue J, McGrath M, Weston S, Piedra PA, Desai C, Callahan K, Lewis M, Price-Abbott P, Formica N, Shinde V, Fries L, Lickliter JD, Griffin P, Wilkinson B, Glenn GM. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020 Dec 10;383(24):2320-2332. doi: 10.1056/NEJMoa2026920. Epub 2020 Sep 2.
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Development
Address 0 0
Novavax
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04368988